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T. Angelica Herbal Tonic (TAHT) is a herbal product indicated for indigestion and constipation and highly patronized in Nigeria.
In this study, the eﬃcacy and safety ofthe herbal tonic in relation to the label claimswere assessed.The eﬀect on peristalsisin mice
was evaluated by the charcoal meal model and in vitro using guinea pig ileum. The eﬀects of TAHT onbehavior, fertility, birth and
organ weights were also determined. Teratogenic potential and reproductive toxicity were studied in pregnant rats. Acute toxicity
studies showed that at doses above 5000mgkg−1, the herbal tonic did not cause lethality and produced no signs of intoxication
in mice. The study did not show any gross behavioral changes in mice treated with 1000mgkg−1 of TAHT as compared with the
negative control treatment. TAHT (400mgkg−1) exhibited a dose-dependent enhancement in the gastrointestinal tract motilityin
micewhen compared with thenegative control.At concentrationsup to 300μgmL −1,TAHT did notcauseanysigniﬁcanteﬀect on
acetylcholine, histamineandnicotine-evoked contractionsofguinea pig ileum preparation.It took anaverageof31.25 ± 4.52 days
for the TAHT-treated animals to litter, which is signiﬁcantly (P < .05) diﬀerent from the 55 ± 4.51 days recorded for the control
treatment group. TAHT exhibited a modest fertility-promoting eﬀect and showed lack of abortifacient and teratogenic properties
in the study. Generally, the results of this study showed some favorable pharmacological eﬀects of TAHT in animals which may
authenticate some of the label claims.
1.Introduction
Historically, herbal medicine has been an important com-
ponent of healthcare all over the world. With the advances
in medical and biological sciences that resulted in the
introduction of promising synthetic orthodox therapies for
many conditions, the use of herbal medicine declined in the
20th century. Lately, however, there has been a resurgence
of interest in the use of phytomedicinal products in the
treatment of diseases [1, 2]. The World Health Organization
(WHO) has documented the rapidly growing interest and
economic importance of Traditional Medicine (TM) in
health systems all over the world.
In Africa, a WHO report estimated that up to 80% of
the population use TM to help meet their health care needs
either alone or in combination with orthodox therapies
[3,4].Asian andLatinAmericanpopulationscontinuetouse
TMasaresultofhistoricalcircumstancesandculturalbeliefs.
In China, TM accounts for ∼40% of all health care services
delivered. In many developedcountries, complementary and
alternative medicines (CAMs) is also becoming more and
more popular. The percentage of the population which has
used CAM at least once is 48% in Australia, 70% in Canada,
42% in USA, 38% in Belgium and 75% in France. In many
parts of the world, expenditure on TM/CAM is not only
signiﬁcant, but also growing rapidly. In Australia, Canada
and the UK, annual CAM expenditure is estimated at US$
80, US$ 2400 and US$ 2300 million, respectively [5, 6].
With the increasing popularity and patronage of com-
mercially promoted herbal medications, the need for the
assessment of the safety and quality of these products
is increasingly being felt. The safety evaluation of herbal
products is even more important since the popular belief
that herbal therapies are without untoward eﬀects have2 Evidence-Based Complementary and Alternative Medicine
often been proven incorrect [7, 8]. Assurances of safety,
eﬃcacy and quality of herbal medicines have been limited by
lack of research methodology, inadequate evidence base for
TM/CAM therapies and products, lack of international and
national standards, lack of adequate regulation and registra-
tion of herbal medicines, lack of registration of TM/CAM
providers and inadequate support for such research eﬀorts
[9, 10].
T. Angelica Herbal Tonic (TAHT) is an amber-colored
liquid preparation with slight bitter taste, packaged in
750mL amber colored plastic bottle. TAHT is promoted as
a mild laxative with: “aids digestion”, “relieves constipation”,
“eliminatesbloatness”,and“enhancesbowelcleansing”askey
label indications. TAHT is labeled to contain Doundake root
(3.71%)and Cassia acutifolia (1.0%)astheactive ingredients
and Kalii nitras (0.073%), Methyl paraben (0.2%), Propyl
paraben(0.02%)and deionizedwater as inactive ingredients.
This herbal product is highly patronized in Nigeria and is
claimed to be useful for a variety of purposes by the public.
This stimulated the interest in conducting an investigation
into the safety and eﬃcacy of the products in relation to the
claim of this product using laboratory animal models.
2.Materialsand Methods
2.1. The Product. TAHT is an amber colored liquid prepara-
tion with a slightly bitter taste. It is packaged in an amber
plastic bottle of 750mL capacity, closed with a tamper-
proof aluminum screw cap. Each 150mL of the preparation
contains Doundake root obtained from Nauclea latifolia
(5.56g, equivalent to 2.36mg/mL total alkaloid) and C.
acutifolia leaf (1.5g, equivalent to 3.075% sennoside B). In
this study, the dosing of the TAHT to animals was based on
the total active ingredient content per milliliter of the tonic.
Permission to undertakethestudy was obtained from the
manufacturer, HErBALINE Nigeria Ltd, and samples used
in the study were obtained from the manufacturer’s direct
supply chain.
2.2.Animals. Adultalbinorats(100–200g),albinomice(21–
25g) and guinea pigs (220–280g) of both sexes, obtained
from the Laboratory Animal Facility of the Department of
Pharmacology andToxicology,UniversityofNigeria,Nsukka
were used in the study. The animals were housed under
standard conditions (25 ± 2◦C and 12-h light/dark cycle).
The rats and mice were maintained on standard pellets
(Livestock feed), while guinea pigs were fed with guinea
grass (Panicum maximum L.). All animals were allowed
unrestricted access to drinking water. The use and care of
laboratory animals in the study were in accordance with the
ethical guidelines contained in the European Convention for
the Protection of Vertebrate Animals used for Experimental
and Other Scientiﬁc Purposes (EEC Directive of 1986;
86/609/EEC)as amended in the European Treaty Series(ETS
no. 170) of 2005.
2.3. Acute Toxicity Determination. The acute toxicity study
of TAHT was assessed by oral administration in albino
mice using the Lorke (1983) method [11]. Brieﬂy, the tests
involved two phases. The ﬁrst phase is the determination of
the toxic range. The mice were placed in three groups (n =
3) and were administered TAHT (10, 100 and 1000mgkg−1)
orally. The treated mice were observed for 24h for the
number of deaths. The death pattern in the ﬁrst phase
determined the doses used for the second phase according to
the Lorke (1983) estimation [11]. In this phase, four groups
(n = 3) of mice were used for each dose. Each group received
diﬀerent doses of the TAHT (p. o.) as predetermined in the
ﬁrst phase and the animals were observed for lethality or
signs of acute intoxication for 24h. The LD50 was calculated
as the geometric mean of the highest nonlethal dose and the
least toxic dose.
2.4. Gastrointestinal Tract Motility. The primary indica-
tion of the herbal tonic is for bowel cleansing, relief of
constipation and mild purgation. This necessitated the
investigation of the eﬀect of the TAHT on gastrointestinal
(GI) motility. Sixteen albino mice of either sex (20–30g),
randomly divided into four groups (n = 4) were used in
the study. The animals were starved for 24h prior to the
experiment, but were allowed unrestricted access to drinking
water. The ﬁrst two groups received 200 and 400mgkg−1,
respectively, while the 3rd and 4th groups received carbachol
(40mgkg−1) and normal saline (10mLkg−1). After 5min of
drug administration, 0.5mL of 5% charcoal dispersion in
tragacanth mucilage was administered orally to each animal.
The animals were sacriﬁced 30min later and the abdomen
opened. The percentage distance traveled by the charcoal
plug in the small intestine (from the pylorus to the caecum)
inthetreatment groupsweredeterminedandcomparedwith
the normal saline-treated group used as the negative control.
2.5. Neuropharmacological Activity. Ten mice placed into
two groups (n = 5) were used in the study. The ﬁrst
group was given TAHT (1000mgkg−1, p.o.) and the second
group served as the control and was given normal saline
(20mLkg−1, p.o.). The treated animals were observed for
24h and behavioral parameters (includingawareness, mood,
motor activity, central activity, muscle tone, reﬂexes and
autonomic eﬀects) were monitored.
2.6. Reproductive and Developmental Toxicity Investigation.
These studies assessed TAHT for abortifacient, teratogenic
and deleterious developmental eﬀects. Virgin rats were
divided into two groups (n = 5) and acclimatized for
15 days. During this time, the test group was given oral
dose of TAHT (500mgkg−1)d a i l y( ∼10 times the daily
recommended dose of 60mgkg−1), while the control group
daily received5mLkg−1 ofdistilled waterorally. The animals
were monitored for normal growth and development. After
this period, two mature male rats of proven fertility (based
on earlier ability to cause pregnancies) were introduced into
eachcageandthenumberofdaysthatelapsedbeforedelivery
wasrecordedfortheratsineach group.Duringgestation,the
rats were monitored for incidences of possible spontaneous
abortion. The birth weightoflitters,sex (determined3weeksEvidence-Based Complementary and Alternative Medicine 3
Table 1: The eﬀect of acute dose of TAHT (1000mgkg−1) on the behavioral pattern of mice.
Bahavioral activity Description Control treatment scorea Test treatment scoresa
Awareness Alertness 4 4
Passivity 0 1
Mood Grooming 4 4
Vocalization 0 0
Fearfulness 0 0
Aggressiveness 0 0
Motor activity Inquisitive behavior in unfamiliar environment 0 0
Touch response 4 4
Pain response 4 4
Central activity Response to noise 4 4
Tremor 0 0
Convulsion 0 0
Muscle tone Limb tone 4 4
Grip strength 4 4
Reﬂexes Pinna reﬂex 4 4
Cornea reﬂex 4 4
Autonomic eﬀects Respiratory rate 4 4
Piloerection 0 0
Writhing 0 0
aThe scores were recorded on a scale of 0–8 with a base score of a normal response as 4.
Table 2: Eﬀects of TAHT on gastrointestinal motility in mice.
Agents Dose (mg kg−1) Percentage of intestinal transit
Carbachol 40 73.03 ± 5.72∗
Normal saline 20mLkg−1 56.02 ± 6.88
TAHT 200mgkg−1 65.90 ± 4.02
TAHT 400mgkg−1 70.93 ± 2.71∗
Albino mice were placed randomly into four groups and were starved
for 24h prior to the experiment. The ﬁrst two groups received 200 and
400mgkg−1 oftheTAHT,respectively,whilethe3rdand4thgroupsreceived
carbachol(40mgkg−1) andnormal saline(10mLkg−1).After5minofdrug
administration, 0.5mL of 5% charcoal dispersion in tragacanth mucilage
was administered orally to each animal. The animals were sacriﬁced 30min
laterandthe percentage of distancetraveledby the charcoal pluginthesmall
intestine (from the pylorus to the caecum) were determined and compared
with the negative control.
∗Signiﬁcant P < .05 versus control.
after birth) and total number of litters were recorded. The
litters were also observed for incidences of malformation.
Daily oral administration of TAHT continued while animals
were lactating. The litters were also observed for growth and
developmentfor a period of 3 weeks. At the end of the study,
theadultfemale ratswere sacriﬁced and gross morphological
examinations carried out on the major organs (heart, lungs,
spleen, liver and kidney); the weights of the organs were also
determined.
2.7. In Vitro Pharmacological Experiments
2.7.1. Guinea Pig Ileum Activity. This study was conducted
to determine the eﬀects of TAHT on the smooth muscle
of GIT. Segments of ileum isolated from freshly sacriﬁced
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Figure1:Increaseinweightofvirginratsduringtheadministration
of THAT before mating.
guinea pig were suspended in 30mL organ bath containing
Tyrode’s solution at 37 ± 1◦C aerated with air. The eﬀect
of TAHT on the isolated tissue was studied according to
classical methods. Increasing concentrations of TAHT up to
300μgmL −1 w e r ea d d e di n t ot h eo r g a nb a t ht od e t e r m i n ei t s
eﬀect on isolated ileum. The eﬀect of TAHT on contractions
produced by standard agonists: acetylcholine (0.3μgmL −1),
histamine (0.06μgmL −1) and nicotine (30μgmL −1)w e r e
also studied.
2.7.2. Gravid Rat Uterus Activity. T h ep o s s i b l ee ﬀect of
TAHT on intrinsic rhythmic contraction of isolated gravid
uterus, and therefore the assessment of possible tocolytic or4 Evidence-Based Complementary and Alternative Medicine
Table 3: Summary of reproductive eﬀects of TAHT in experimental rats.
Parameter Control group Test group
Number of virgin rats 5 5
Percentage of pregnancy at the end of experiment 80 80
Percentage of pregnant by the 43rd day 0 80
Percentage of pregnant by the 65th day 80 80
Mean number of days elapsed before delivery 55.00 ± 4.71 31.25 ± 4.52∗
Total litter size 21 30
Average litter size 5.25 ± 0.95 7.50 ± 0.50
Number of male litters 10 16
Number of female litters 11 14
Average birth weight (g) 5.95 ± 0.10 4.81 ± 0.19∗
Percentage increase in weight 21 days after birth 364.53 ± 10.01 390.74 ± 34.47
Percent weight of major organs (relative to body weight)
(i) Heart 0.463 ± 0.024 0.358 ± 0.017∗
(ii) Kidney 0.639 ± 0.037 0.595 ± 0.020
(iii) Lung 0.646 ± 0.020 0.750 ± 0.022
(iv) Spleen 0.297 ± 0.024 0.304 ± 0.008
(v) Liver 5.185 ± 0.147 4.17 ± 0.152∗
Duration of pregnancy (days) in each of the four pregnancies achieved in both groups (counting from the start of mating)
(i) First animal 46 21
(ii) Second animal 48 30
(iii) Third animal 61 31
(iv) Fourth animal 65 43
∗Signiﬁcant P < .05 versus control.
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Figure 2: Percentage increase in the weight of the litters over a 21-
day monitoring period.
abortifacient properties was also determined. The two horns
ofuterusisolated from a freshly sacriﬁced gravid rat were cut
longitudinally into strips. A strip was mounted in De Jalon’s
solution and the eﬀect of increasing concentrations of TAHT
onthe spontaneous rhythmic contractionof theuterinestrip
was monitored.
2.8. Statistical Analysis. Data were analyzed by analysis of
variation, ANOVA using SPSS (version 11) and diﬀerences
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Figure 3: Percentage weight of the organs (relative to the body
weight) of the rats after sacriﬁce.
between paired observations were regarded as signiﬁcant at
P ≤ .05.
3.Results
3.1. Toxicity of TAHT. At doses above 5000mgkg−1,t h e
herbal tonic did not cause lethality and produced no signs
of acute intoxication in the mice. Therefore, TAHT could
generally be regarded as safe. The study did not show anyEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: The eﬀect of THAT (cumulative) on intrinsic contractility of the gravid rat uterus. A sample tracing showing the treatment of rat
uterine strips with increasing amount of (1–8 mg) of THAT, PGF2α and Salbutamol. THAT did not aﬀect the frequency and amplitude of
uterine strips inherent contractility.
gross behavioral changes in mice treated with 1000mgkg−1
of TAHT as compared with the negative control treatment
(Table 1).
3.2. TAHT Improves GIT Motility. The TAHT exhibited a
dose-dependent enhancement in the GI tract (GIT) motility
in mice. The increase in the intestinal motility induced
b yt h eh i g h e rd o s e( 4 0 0 m g k g −1)w a ss i g n i ﬁ c a n t( P <
.05) when compared with the negative control; however,
the eﬀect was slightly below the increase in peristalsis
produced by carbachol 40mgkg−1, a standard muscarinic
agonist (Table 2). Addition of TAHT at concentrations up
to 300μgmL −1 did not produce any signiﬁcant eﬀect on
acetylcholine,histamine andnicotine-evokedcontractionsof
guinea pig ileum preparation.
3.3. Reproductive and Developmental Activity of TAHT.
There was no signiﬁcant diﬀerence (P > .05) in the increase
in the weight of the virgin rats treated with TAHT and
the control treatment after a 15-day monitoring period
(Figure1).Italso tookan averageof31.25 ± 4.52daysforthe
test (treated) animals to litter. This is signiﬁcantly (P < .05)
diﬀerent from the 55 ± 4.51 days that elapsed before delivery
was recorded for the control treatment group. By the 43rd
day ofmating, 80% ofthe rats in the test grouphad delivered
while none delivered in the control group (Table 3). The
meanweightofthelittersinthecontrolgroup(5.95 ±0.09g)
was found tobe signiﬁcantly higher (P <.05) thanthat ofthe
test group (4.81 ± 0.19g) (Figure 2). The mean number of
litters was 7.50 ± 0.05 and 5.25 ± 0.95 in the test and control
groups, respectively (Table 3). Subsequent monitoring of the
litters in both groups showed that there was no signiﬁcant
diﬀerence in the percentage increase in weight over the 21-
dayobservationperiod(Table3andFigure2),indicatinglack
of developmental eﬀect on lactating animals (Table 3).
No spontaneous abortion or malformation was noted
in any of the pregnant rats and litters in both groups.
The results indicate that TAHT lacks abortifacient and
teratogenic properties. Gross morphological examination of
the major organs showed no diﬀerence in the organs from
both the control and the test animals. However, signiﬁcant
diﬀerences (P < .05) were noted in the mean weight of the
heart and liver, where higher mean values were recorded for
the control group animals (Figure 3).
3.4. Activity of TAHT on Uterine Strips. TAHT did not
modify the intrinsic contractility of isolated uterine prepa-
rations. In the experiment, salbutamol (a tocolytic agent)
completely relaxed the uterine strip while prostaglandin
F2α (PGF2α), a typical abortifacient, also caused sustained
increase in amplitude and frequency of the uterine muscle
strip contraction (Figure 4).
4.Discussion
Inthestudyonmice,TAHTwithLD50 > 5000mgkg−1 could
be considered safe [11]. Although safety studies in animal
models could often be extrapolated to humans, it does not
necessarily follow that such products would be completely
safe in humans. Therefore, actual controlled clinical trials on
human subjects would be more deﬁnitive evidence on safety.
TAHT did not cause the contraction of guinea pig ileum
preparation and did not produce any signiﬁcant eﬀect on
acetylcholine,histamineandnicotine-evokedcontractionsof
the tissue. This result suggests that the pro-kinetic eﬀect of6 Evidence-Based Complementary and Alternative Medicine
TAHT on GIT may not be mediated by a direct eﬀect on
muscarinic, histaminergic or nicotinic receptorsstimulation.
Although the laxative eﬀect of TAHT recorded in the whole
animal experiments could support the beneﬁts claimed in
the use of TAHT for indigestion, constipation and bloating
of stomach, the exact mechanism by which TAHT induces
increase in the intestinal motility is not clear from the study.
The lower mean birth weights recorded in the group
treated with TAHT could be ascribed to the higher number
of litter size (a total of 30 for test group and 21 for control
group), since higher multiple pregnancy could lead to lower
mean birth weights. Subsequent monitoring of the litters in
both groups showed that there was no signiﬁcant diﬀerence
in the percentage increase in weight over 21-day observation
period, indicating lack of developmental eﬀect on lactating
animals. Although the study demonstrates some fertility
promotion eﬀect of TAHT, more studies will be required to
deﬁnitively conﬁrm any possible eﬀect on sexuality, fertility
and fertility hormones. The study also showed that TAHT
lacks abortifacient and teratogenic eﬀects.
TM and CAM are now attracting increasing attention
and many governments are now according relevance to
CAM in the provision of health care all over the world
[12]. Some important issues must be addressed if the
potentials of TM/CAM are to be developed successfully. It
is known that herbs in their natural state vary in potency
andmay containmultiplepharmacologicalsubstanceswhich
can cause undesirable eﬀects. In most instances, herbal
medicines are not made with isolated and puriﬁed active
substance that will permit standardization of dosages, and
testing for safety and eﬃcacy before approval [13]. Some
toxic reactions to the use of herbal remedies are related to
improper preparation, excessive quantities of some herbs,
substitution of a herb with related herbs believed to possess
similar eﬀects and the eﬀect of using herbal medications
concomitantly with other pharmacologic products [14, 15].
In this study, a scientiﬁc assessment of a highly patron-
ized herbal preparation marketed and used in Nigeria was
undertaken. The results of this study show some level of
eﬃcacy and safety, which are related to some of the claimed
indications of the phytomedicine. The results also showed
some favorable pharmacological eﬀects in animal models,
which authenticates some of the label claims. However,
further exhaustive studies, especially in human volunteers,
would be necessary to succinctly validate the safety and
eﬃcacy of this herbal tonic.
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